CompanyGraph
What stands out
- Valued far above the size of its business
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
- ScaleRevenue is $10.36M, lower than 95% of all stocks globally
- FinancialsLow earnings quality
- Interpretations2 currently firing — 2
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
What stands out
- Valued far above the size of its business
Financials view
Market Capitalization
323.57MUSDvs all stocks (USD)
Revenue (TTM)
10.36MUSDvs all stocks (USD)
Profit Margin
0.00%52-Week Change
29.36%vs all stocks
Market Capitalization
323.57MUSDvs all stocks (USD)
Enterprise Value
15.01MUSDvs all stocks (USD)
Forward P/E
-2.96xPrice to Sales (TTM)
31.69xPrice to Book (MRQ)
0.8730xEnterprise to Revenue
1.45xEnterprise to EBITDA
-0.1420xProfit Margin
0.00%Operating Margin
-1196.78%Return on Assets (TTM)
-18.47%Return on Equity (TTM)
-28.21%Revenue (TTM)
10.36MUSDvs all stocks (USD)
Revenue per Share (TTM)
0.2600USDUpdated Sep 27, 2026Quarterly Revenue Growth
1.60%Gross Profit (TTM)
-77.43MUSDvs all stocks (USD)
EBITDA (TTM)
-106.02MUSDvs all stocks (USD)
Net Income (TTM)
-94.46MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
1.62%Operating Cash Flow (TTM)
-87.60MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-58.07MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Sep 27, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%Revenue
8.99MUSDFY2025 · Dec 31, 2025Operating Income
-92.78MUSDvs all stocks (USD)
Pre-tax Income
-80.61MUSDFY2025 · Dec 31, 2025Net Income
-80.61MUSDFY2025 · Dec 31, 2025EBIT
-79.91MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-79.48MUSDFY2025 · Dec 31, 2025Research & Development
73.97MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
27.81MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
13.09MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
697.00KUSDFY2025 · Dec 31, 2025Net Income from Continuing Operations
-80.61MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-76.74MUSDFY2025 · Dec 31, 2025Free Cash Flow
-77.46MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
188.89MUSDFY2025 · Dec 31, 2025Interest Paid
611.00KUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-80.61MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
213.00KUSDFY2025 · Dec 31, 2025Stock-based Compensation
11.69MUSDFY2025 · Dec 31, 2025Other Non-cash Items
-1.33MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-769.00KUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
788.00KUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-6.72MUSDFY2025 · Dec 31, 2025Capital Expenditures
-719.00KUSDFY2025 · Dec 31, 2025Purchase of Investments
-154.75MUSDFY2025 · Dec 31, 2025Sale of Investments
60.25MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-95.22MUSDFY2025 · Dec 31, 2025Long-term Debt Payments
-6.00MUSDFY2025 · Dec 31, 2025Other Financing Charges
-400.00KUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
10.76MUSDFY2025 · Dec 31, 2025Shares Outstanding
45.78MSharesUpdated Sep 27, 2026Float Shares
39.19MSharesUpdated Sep 27, 2026Shares Short
3.07MSharesUpdated Sep 27, 2026Short Ratio
5.60daysvs all stocks
Short % of Shares Outstanding
7.53%vs all stocks
% Held by Insiders
2.36%vs all stocks
% Held by Institutions
90.58%vs all stocks
Total Cash (MRQ)
318.74MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
6.95USDUpdated Sep 27, 2026Total Debt (MRQ)
2.83MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.0076xCurrent Ratio (MRQ)
17.19xBook Value per Share (MRQ)
8.19USDUpdated Sep 27, 2026Total Assets
294.89MUSDvs all stocks (USD)
Total Current Assets
286.79MUSDFY2025 · Dec 31, 2025Total Liabilities
22.84MUSDFY2025 · Dec 31, 2025Total Non-current Assets
8.10MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
2.70MUSDFY2025 · Dec 31, 2025Total Current Liabilities
20.14MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
188.89MUSDFY2025 · Dec 31, 2025Other Short-term Investments
92.21MUSDFY2025 · Dec 31, 2025Accounts Receivable
769.00KUSDFY2025 · Dec 31, 2025Accounts Payable
2.67MUSDFY2025 · Dec 31, 2025Short-term Debt
3.23MUSDFY2025 · Dec 31, 2025Deferred Revenue
5.75MUSDFY2025 · Dec 31, 2025Other Current Liabilities
525.00KUSDFY2025 · Dec 31, 2025Long-term Debt
2.33MUSDFY2025 · Dec 31, 2025Common Stock (Book)
0.00USDFY2025 · Dec 31, 2025Retained Earnings
-333.42MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
272.05MUSDvs all stocks (USD)
52-Week Low
5.04USDUpdated Sep 27, 202652-Week High
25.95USDUpdated Sep 27, 202652-Week Change
29.36%vs all stocks
50-Day MA
12.39USDUpdated Sep 27, 2026200-Day MA
16.87USDUpdated Sep 27, 2026Avg 10-Day Volume
787.65KSharesUpdated Sep 27, 2026Avg 30-Day Volume
621.46KSharesUpdated Sep 27, 2026Diluted EPS (TTM)
-2.39USDUpdated Sep 27, 2026Other Income / Expense
-214.00KUSDFY2025 · Dec 31, 20252 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsWhere is this company structurally exposed?
Decline With Range Expansion And Drawdown
The price is falling, swinging wider than usual, and sits well below its peak.
Ulcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
It sits well below its peak, and the fall has been both deep and long.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
Valued far above the size of its businessSignificant
Price-to-Sales: 31.69Revenue Growth YoY: 0.02
Financial Health
Low earnings qualitySignificant
Earnings Quality Score: -0.59
Altman Z-Score 7.14: safe zoneNotable
Altman Z-Score: 7.14
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Scale
Revenue is $10.36M, lower than 95% of all stocks globallySignificant
Revenue (USD): 10,355,000Global P5: 33,357,653.812
Companies that share the same coordination system — how they create, deliver, or capture value.
Il Dong Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Newron Pharmaceuticals SpA
Tier 1ProductionApproval-Gated PipelineRuleRisk
Golden Throat Holdings Group Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Dishman Carbogen Amcis Ltd.
Tier 1ProductionApproval-Gated PipelineFlowRule
Larimar Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Hubei Guangji Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Cuorips Inc.
Tier 1ProductionApproval-Gated PipelineRule
Green Cross Holdings Corp.
Tier 1ProductionApproval-Gated PipelineRuleFlow
BridgeBio Oncology Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Enwei Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Anbio Biotechnology Limited
2 interpretationsDecline With Range Expansion And DrawdownUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
Md Entertainment Tbk
2 interpretationsDecline With Range Expansion And DrawdownUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
Wintao Communications Co.
2 interpretationsDecline With Range Expansion And DrawdownUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated